May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” BIVV009 is a safe treatment for bullous pemphigoid that reduces C3 deposition without harmful side effects.
September 2024 in “LUTS Lower Urinary Tract Symptoms” People with hair loss may have worse urinary symptoms due to an enlarged prostate.
August 2024 in “Australasian Journal of Dermatology” Finasteride users have a very low risk of mental health issues, but those with hair loss may have slightly higher anxiety and depression.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
May 2024 in “KIU journal of health science” Kolaviron and quercetin may help treat prostate issues.
April 2024 in “The Journal of urology/The journal of urology” SRD5A2 methylation in blood can predict how well someone will respond to finasteride treatment.
April 2024 in “International journal of impotence research” Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.
April 2024 in “Clinical dermatology review (Print)” Trichoscopy is an effective, noninvasive method for early diagnosis of Female Pattern Hair Loss.
October 2023 in “Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy” New, eco-friendly methods accurately measure TDF and FNS in a new urologic medication.
August 2023 in “Malaysian Journal of Medicine and Health Sciences/Malaysian journal of medicine and health sciences” Pueraria mirifica extract may help treat benign prostatic hyperplasia.
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
April 2023 in “Jordan Medical Journal” Men with male pattern baldness are more likely to have benign prostatic hyperplasia.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
November 2021 in “Pharmaceutical Sciences” New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.
Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.
March 2020 in “StatPearls” Medicines called 5-alpha-reductase inhibitors, like finasteride and dutasteride, are useful for treating enlarged prostate and male pattern hair loss.
Androgens increase norepinephrine release, promoting smooth muscle growth in male sex organs, which may contribute to benign prostatic hypertrophy.
August 2019 in “Journal of Investigative Dermatology” The study found that tight junctions reach the top layer of the skin's stratum granulosum, not just the second top layer as previously thought.
May 2019 in “Journal of clinical oncology” Topical calcitriol was safe and well-tolerated for potential hair loss prevention in chemotherapy patients.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
January 2018 in “Universidad Privada Antenor Orrego” Male pattern baldness may be an early sign of noncancerous prostate enlargement.
October 2017 in “The Journal of Urology” Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
April 2017 in “Journal of Dermatological Science” Benzoyl peroxide and adapalene gels work differently to reduce acne in mice.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
April 2017 in “The Journal of urology/The journal of urology” 5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.
January 2017 in “The journal of sexual medicine” Many patients with lower urinary tract symptoms also have undiagnosed erectile dysfunction, which improves with treatment.
January 2016 in “Archivio italiano di urologia, andrologia” The document concludes that the risk of sexual side effects from 5-alpha-reductase inhibitors is low and often temporary, but more research is needed on potential permanent effects.
April 2013 in “The Journal of Urology” Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.
November 2012 in “The Journal of Urology” Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.
September 2012 in “African Journal of Urology” Testosterone replacement therapy improves libido, mood, muscle strength, and bone density in men with Testosterone Deficiency Syndrome.